Date: 2015-08-11
Type of information: Development agreement
Compound: Centyrin technology
Company: Janssen Biotech, a J&J company (USA - NJ) Poseida Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D development licensing commercialisation
Action mechanism: Centyrins are a class of Janssen proprietary alternative scaffold molecules that can be engineered to bind to target proteins with an interface of similar size to those used by antibodies. Critical to the use of Centyrins to treat human disease, Janssen has developed a number of Centyrin libraries that are used for in vitro selection of Centyrin molecules that bind to protein targets with high affinity and specificity.
Disease: multiple myeloma
Details: * On August 11, 2015, Poseida Therapeutics, a private biotechnology company spun out of Transposagen Biopharmaceuticals, announced they have entered into a worldwide License Agreement with Janssen Biotech to research, develop, manufacture and commercialize licensed products using Janssen Centyrin technology. Poseida has entered into an exclusive license to use Centyrins to develop pharmaceutical products containing or comprised of autologous T-cells or any NK- or NK-like cells expressing a Centyrin molecule or Centyrin Chimeric Antigen Receptor (CAR) molecule. CAR therapies have shown promise in early human clinical trials for the treatment of blood cancers. As part of the Centyrin license, Poseida will gain access to Centyrin molecules against three existing targets, including one that Poseida is developing in house as part of an autologous CAR-T therapy to treat multiple myeloma. Under the license Agreement, Poseida gains the rights to screen the Centyrin library to identify and develop Centyrin molecules against new cancer antigens that Poseida identifies or licenses, including solid tumor antigens.
Financial terms: Poseida will pay Janssen an undisclosed upfront fee and potential development, regulatory, and commercial milestone payments.
Latest news:
